Gastrointestinal applications of nanoparticulate drug-delivery systems

Nanoparticulate Drug Delivery Systems

Volumn , Issue , 2007, Pages 305-316

  Gasco, Maria Rosa ^a  

^a NANOVECTOR S R L   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77549085379     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (65)

1. Kreuter J. Peroral administration of nanoparticles. Adv Drug Deliv Rev 1991; 7:71.
2. Hussain N, Jaitely B, Florence AT. Recent advances in understanding the uptake of mic-roparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev 2001; 50:107.
3. Florence AT, Hussain N. Trancytosis of nanoparticle and dendrimer systems: evolving vistas. Adv Drug Deliv Rev 2001; 50:S69.
4. Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulate systems. Adv Drug Deliv Rev 2001; 47:55.
5. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Sol St Mater Sci 2002; 6:319.
6. Florence AT. Issues in oral nanoparticles: drug carrier uptake and targeting. J Drug Target 2004; 12:65.
7. Uchida J. Electron microscopic study of microfold cells (M cells) in normal and inflamed human appendix. Gastroenterol Jpn 1988; 23:251.
8. Watts PJ, Illum L. Colonic drug targeting. Drug Dev Ind Pharm 1997; 23:893.
9. Patri AK, Majoros IJ, Baker JR. Dendritic polymer carriers for drug delivery. Curr Opin Chem Biol 2002; 6:466.
10. Gillies ER, Frachet JM. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 2005; 10:35.
11. Tripathi PK, Khopade AS, Nagaich S, et al. Dendrimer grafts for delivery of 5-fluorouracil. Pharmazie 2002; 57:261.
12. Bala I, Hariharan S, Kumar R. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 2004; 21:387.
13. Vauthier C, Dubernct C, Fattal E, et al. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev 2003; 55:519.
14. Delie F, Blanco-Prieto MJ. Polymerie particulates to improve oral bioavailability of peptide drugs. Molecules 2005; 10:65.
15. Takeuki H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 2001; 47:39.
16. Damge C, Vranks H, Balschmit P, et al. Poly(alkylcyanoacrylate) nanospheres for oral administration of insulin. J Pharm Sci 1997; 86:1403.
17. Pinto-Alphandary H, Aboubakar M, Jallar D, et al. Visualization of insulin loaded nano-capsules: in vitro and in vivo studies after oral administration to rats. Pharm Res 2003; 20:1071.
18. Li Y, Jang HL, Jin JE, et al. Bioadhesive fluorescent microspheres as visible carriers for local delivery of drugs-uptake of insulin loaded PCEFB/PLGA microspheres by the gastrointestinal tract. Drug Deliv 2004; 11:335.
19. Damge C, Aphrahamian, Marchais H, et al. Poly(alkylcyanoacrylate) nanocapsules as a delivery system for octreoctide, a long acting somatostatin analogue. J Pharm Pharmacol 1997; 49:949.
20. Sang Yoo H, Gwan Park T. Biodegradable nanoparticles containing protein-fatty acid complexes for oral delivery of salmon calcitonin. J Pharm Sci 2004; 93:488.
21. El-Shabouri MH. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int J Pharm 2002; 249:101.
22. Ubrich N, Schmidt C, Bodmeier R, et al. Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS or RL nanoparticles. Int J Pharm 2005; 288:169.
23. Jiao Y, Ubrich N, Marchand-Arvier M, et al. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 2002; 105:230.
24. Foster N, Hirst BH. Exploiting receptor biology for oral vaccination with biodegradable particulates. Adv Drug Deliv Rev 2005; 57:431.
25. Fooks AR. Development of oral vaccine for human use. Curr Opin Mol Ther 2000; 2:80.
26. Tabata Y, Inoue Y, Ikada Y. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine 1996; 14:1667.
27. Gutierro I, Hernandez RH, Igartua H, et al. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 2002; 21:67.
28. Allen TM. Liposomes opportunity in drug-delivery. Drugs 1997; 54(suppl 4):8.
29. Barratt GM. Therapeutic applications of colloidal drug carriers: physical structure to therapeutic applications. Pharm Sci Technol Today 2000; 3:163.
30. Taira MC, Chiaramonti NS, Fecuch KM, et al. Stability of liposomal formulations in physiological conditions for oral drug delivery. Drug Deliv 2004; 11:123.
31. Cansell M, Nacka F, Combe N. Marine lipid-based liposomes increase in vivo FA bioavailability. Lipids 2003; 38:551.
32. Takeuchi H, Matsui Y, Yamamoto H, et al. Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in oral administration of calcitonin to rats. J Control Release 2003; 86:235.
33. Li H, Son JH, Park JS, et al. Polyethylene glycol-coated liposomes for oral delivery of recombinant human epidermal growth factor. Int J Pharm 2003; 258:11.
34. Yamabe K, Kato Y, Onishi H, et al. Potentiality of double liposomes containing salmon calcitonin as an oral dosage form. J Control Release 2003; 89:429.
35. Gershanik T, Benita S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm 2000; 50:179.
36. Lawrence MJ, Rees GD. Microemulsion-based media as novel delivery systems. Adv Drug Deliv Rev 2000; 45:89.
37. Gao P, Rush PD, Pfund W, et al. Development of a supersaturable SEDDS formulation of paclitaxel with improved bioavailability. J Pharm Sci 2003; 92:2386.
38. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004; 58:173.
39. Kang BK, Lee JS, Chron SK, et al. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm 2004; 274:65.
40. Muller RH, Karsten M, Sven G. Solid-lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000; 50:161.
41. Bummer PM. Chemical consideration of lipid-based oral drug delivery-solid-lipid nanoparticles. Crit Rev Ther Drug Carrier Syst 2004; 21:1.
42. Manjunath K, Reddy JS, Venkateswarlu V. Solid-lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol 2005; 27:127.
43. Yang S, Zhu J, Lu Y, et al. Body distribution of camptothecin solid-lipid nanoparticles after oral administration. Pharm Res 1999; 16:751.
44. Demirel M, Yazan Y, Muller RH, et al. Formulation and in vitro-in vivo evaluation of piribedil solid-lipid micro and nanoparticles. J Microencapsul 2001; 18:359.
45. Hu L, Tang X, Cui F. Solid-lipid nanoparticles to improve bioavailability of poorly soluble drugs. J Pharm Pharmacol 2004; 56:1527.
46. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid-lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 2006;14:632
47. Bekerman T, Golenser J, Domb A. Cyclosporin nanoparticulate lipospheres for oral administration. J Pharm Sci 2004; 93:1264.
48. Siekman B, Westesen K. Investigation on solid-lipid nanoparticles prepared by precipitation in o/w emulsion. Eur J Pharm Biopharm 1996; 43:104.
49. Hu FQ, Yuan H, Zhang RH, et al. Preparation of solid-lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharm 2002; 239:121.
50. Gasco MR. Method for producing solid-lipid microspheres having narrow size distribution. US Patents 1993;5,250,236.
51. Gasco MR. Solid-lipid nanospheres from warm microemulsions. Pharm Tech Eur 1997; 9:52.
52. Gasco MR. Solid-lipid nanoparticles for drug delivery. Pharm Tech Eur 2000; 13:32.
53. Serpe L, Laurora S, Pizzimenti S, et al. Cholesteryl butyrate solid-lipid nanoparticles as a butyric acid pro-drug: effects on cell proliferation, cell-cycle distribution and c-myc expression in human leukemic cells. Anticancer Drugs 2004; 15:525.
54. Serpe L, Catalano MG, Cavalli R, et al. Cytotoxicity of anticancer drugs incorporated in solid-lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm 2004; 58:673.
55. Dianzani C, Cavalli R, Zara GP, et al. Cholesteryl butyrate nanoparticles enhances butyrate inhibition of neutrophils adhesion to endothelium. Br J Pharmacol. 2006;148:648
56. Bargoni A, Cavalli R, Caputo O, et al. Solid-lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res 1998; 15:745.
57. Cavalli R, Zara GP, Caputo O, et al. Transmucosal transport of tobramycin incorporated in SLN after duodenal administration to rats. Part I. A pharmacokinetic study. Pharmacol Res 2000; 42:541.
58. Cavalli R, Bargoni A, Podio V, et al. Duodenal administration of solid-lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci 2003; 92:1085.
59. Bargoni A, Cavalli R, Zara GP, et al. Transmucosal transport of tobramycin incorporated in solid-lipid nanoparticles (SLN) after duodenal administration to rats. Part II. Tissue distribution. Pharmacol Res 2001; 43:497.
60. Zara GP, Bargoni A, Cavalli R, et al. Pharmacokinetics and tissue distribution of idarubicin loaded solid-lipid nanoparticles after duodenal administration to rats. J Pharm Sci 2002; 91:1024.
61. Xing L, Dawei C, Liping X, et al. Oral colon-specific drug delivery for bee venom peptide: development of a coated calcium alginate gel beads-entrapped liposome. J Control Release 2003; 93:293.
62. Lamprecht A, Ubrich N, Yamamoto H, et al. Size dependent targeting of micro and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res 2001; 18:788.
63. Lamprecht A, Ubrich N, Yamamoto H, et al. Design of rolipram loaded nanoparticles: comparison of two preparation methods. J Control Release 2001; 71:297.
64. Lamprecht A, Ubrich N, Yamamoto H, et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2001; 299:775.
65. Royce ME, Hoff PM, Pazdur R. Novel oral chemotherapy agents. Curr Oncol Rep 2000; 2:31.